Poland’s Ministry of Health wants to place medicines with different active substances in a single reimbursement limit group where they work in a similar way, and to reward hospitals for choosing the cheapest therapy available. The change is meant to bring prices down and free up funds for innovative treatment, but clinicians warn that cost equivalence is not the same as clinical equivalence. We examine how the proposed baskets of equivalent therapeutic technologies could affect physicians’ autonomy, patients’ rights and competition in the pharmaceutical market, and what safeguards the legislation should contain. KG LEGAL KIELTYKA GLADKOWSKI supports international pharmaceutical, biotechnology and healthcare businesses operating in Poland. For legal assistance with pharmaceutical regulation, reimbursement and market access, contact our team at office@kg-legal.pl.
Clinical research, diagnostic testing and commercialisation under Polish and EU law
Law as at 5 November 2026
Abstract
A change in an epigenetic clock may justify further investigation of a medicine. Its value as evidence of benefit depends on what the clock measures, the population in which it has been validated and whether treatment effects on the score predict effects on health. The same assay may be used to analyse archived samples, select participants for treatment or sell a test to consumers. Each use raises a different legal question. This article traces those questions from trial design through to commercial use, with particular attention to Polish law on medical experiments, performance studies, access to medical records and the use of data from non-commercial clinical trials.
Keywords ageing biomarkers, geroprotectors, clinical trials, IVDR, biobanks, genetic data
Errors, bias, opacity, data security and the accountability gap – what patients, clinicians and regulators need to watch
Artificial intelligence is already reading scans, ranking medical literature, predicting kidney failure and managing hospital beds. Its potential to make medicine faster, more precise and more personalised seems almost limitless. Yet the same technology brings a distinct set of risks: algorithms that fail silently, tools used without adequate training, models that reproduce existing inequalities, decisions that no one can explain, patient data that is exposed or re-used, and a legal framework that still struggles to say who is responsible when something goes wrong. This article maps those risks and outlines what is needed to manage them.
The development of artificial intelligence in medicine is no longer just a futuristic vision. Algorithms now support diagnostics, test result analysis, and disease prevention, and Polish medical law is beginning to address the challenges involved. The 2025 amendment to the Code of Medical Ethics explicitly addresses the use of AI by physicians for the first time, imposing obligations regarding patient information, obtaining informed consent, and the use of certified systems. However, the question arises: where does the role of technology end and the physician’s responsibility begin?